About PVDOMICS

HISTORY

For many years, it has been recognized that patients with different types of heart and lung diseases exhibit varying degrees of pulmonary vascular disease, leading to changes in the vessels of the lungs, pulmonary hypertension (PH), and right ventricular (the lower chamber of the heart that pumps blood to the lungs) dysfunction. Since 1998, PH has been grouped into classifications that look similar in pathology, hemodynamics, and how the disease is treated. This classification is called the World Symposium Clinical Classification and is updated approximately every five years.

However, the ways by which PH differs from person to person at the genetic, molecular, and cellular level—and how these differences impact the progression of PH—is not as well understood. Recent technological advances have allowed scientists to quickly and cost effectively collect the large amount of genetic, metabolomic, and proteomic information (your genetic information alone contains approximately 3 billion base pairs!), but allow scientists to compare this extraordinarily large amount of data to others similar to you in a process called bioinformatics. Therefore, similarities and differences between patients at the genetic level can be compared with how these same patients differ in their disease as we currently understand it.

In 2010, the NHLBI Pulmonary Vascular Strategic Plan identified the development of a large group of PH patients from whom this large amount of data is collected as a top priority. The NHLBI then issued a “request for proposal” in 2013 for centers interested in participating in developing this network. Ultimately, seven sites were selected as clinical centers and one site as the Data Coordinating Center:

  • Cleveland Clinic (Data Coordinating Center, and Omics Cores including Indiana University)
  • Brigham and Women’s Hospital, Boston
  • Columbia University-New York Presbyterian
  • Weill Cornell Medicine-New York Presbyterian
  • Johns Hopkins University
  • Mayo Clinic
  • University of Arizona
  • Vanderbilt University

Over the next three years, approximately 1,500 participants will be enrolled into the PVDOMICS program, including patients with all types of PH, patients with heart and lung diseases that place them at increased risk of developing PH, and participants without PH (“healthy controls”).

PROTOCOL

Participants in the PVDOMICS study will complete the following tests, most of which are a routine part of PH patient care:

  • Review of medical history, WHO/NYHA functional classification, examination, and medication review
  • Vital signs
  • Body composition
  • Overnight sleep monitoring
  • Pulmonary function tests
  • Tests of exercise tolerance (for example, 6-minute walk test, cardiopulmonary exercise testing)
  • Health-related quality of life surveys
  • Echocardiography
  • Cardiac MRI
  • Lung CT images
  • Ventilation/perfusion (“V/Q”) scan
  • Right heart catheterization
  • Blood draw for “omics measurements”

Study coordinators will work with participants to schedule these tests over 2-4 visits, which should be completed within 6 weeks.

HOW TO PARTICIPATE

To participate in the PVDOMICS study, simply contact one of the participating clinical centers to speak with a research coordinator.

NHLBI Pulmonary Vascular Disease Phenomics Program


Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with support from the Pulmonary Hypertension Association